At least nine significant funding rounds in Q1 2026 brought total BCI investment past $960 million, with capital spreading across invasive, endovascular, ultrasound, and neurostimulation modalities.
The Austin-based company is now enrolling participants at the University of Michigan and Massachusetts General Hospital for the Connect-One study, the first clinical trial of a fully implantable BCI designed to restore speech.
A four-day invitation-only summit modelled on the landmark 1975 DNA conference brings together neuroethicists, investors, and policymakers to create practical governance tools for the BCI industry.
Sam Altman's brain-computer interface startup raised the second-largest BCI round in history. The scientific community is asking whether the physics adds up.
The second annual forum brought together device makers, investors, and six early-stage startups for two days of panels on BCI, neuromodulation, and digital health.
Four philosophers at Glasgow and Oxford will lead a new interdisciplinary lab examining the ethical and epistemological implications of brain-computer interfaces.
The FOCUS-AU trial will test Synchron's advanced brain-computer interface in ten MND patients across three Australian hospitals, with surgery beginning in April.
Five patients now carry the coin-sized wireless implant that sits on the brain's protective membrane rather than penetrating tissue, with one ALS patient decoding nearly 100 Chinese words.
The Pennsylvania company's 60-channel Smart Neurostimulation System is the first device to receive Breakthrough Device Designation for TBI-related memory loss.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.